Cardiometabolic DiseasesEMPOWER-BATNCT07837752
Exercise and Prolonged Fasting to Improve Brown Adipose Tissue Function in Postmenopausal Women
A study testing Aerobic exercise and Prolonged fasting in people with Cardiometabolic Diseases and Postmenopause, run by Universidad de Almeria at 1 site in Spain.
Trial summary
Type of Study: Clinical Trial Goal: The goal of this clinical trial is to investigate mitochondrial function in interscapular brown adipose tissue (iBAT) in postmenopausal women and determine whether aerobic exercise, prolonged fasting, or their combination can improve iBAT mitochondrial function and whole-body… Read more about this study
- Who is it for?
- Ages 45 to 65 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Cardiometabolic Diseases, Postmenopause
- What is being tested?
- Aerobic exercise and Prolonged fasting
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 siteSpain
- Study dates
- 1 Sep 2027to Sep 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 45 to 65 years
- Women only
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Women aged 45 to 65 years.
- Postmenopausal status, defined as ≥ 12 consecutive months without menstruation.
- Women with amenorrhea shorter than 12 months will be included if their follicle-stimulating hormone levels are >30IU/liter.
- BMI between ≥25 kg/m2.
- Sedentary or low-active (not meeting physical activity guidelines).
- Willing to be randomized to any of the four groups.
- Able and willing to adhere to all study procedures and show availabity in their schedule.
- Must be willing to have biological samples stored for future research.
Who cannot join
- Diabetes mellitus (determined based on fasting glucose levels defined by ADA criteria).
- Any other active endocrine disease (thyroid disease, any signs of Cushing's syndrome, adrenal disease and lipid-associated disorders such as familial hypercholesterolemia).
- Any cardiac disease (i.e., ischemic cardiac disease, arrhythmias, severe heart failure).
- Use of medication known to influence glucose and/or lipid metabolism or brown fat activity (e.g., beta-blockers, antidepressants, corticosteroids).
- Current or recent (past 6 months) use of hormone replacement therapy, including systemic estrogen therapy (oral or transdermal), combined estrogen-progestin therapy, tibolone, or selective estrogen receptor modulators.
- Clinically relevant abnormalities in clinical chemistry or electrocardiogram at screening (to be judged by the study physician).
Show all 9Show fewer
- A first-degree family member with sudden cardiac death.
- Any chronic renal or hepatic disease.
- Abuse of alcohol or other substances.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Exercise and Prolonged Fasting to Improve Interscapular Brown Fat Mitochondrial Function and Enhance Metabolic Flexibility in Postmenopausal Women (EMPOWER-BAT)
Type of Study: Clinical Trial
Goal: The goal of this clinical trial is to investigate mitochondrial function in interscapular brown adipose tissue (iBAT) in postmenopausal women and determine whether aerobic exercise, prolonged fasting, or their combination can improve iBAT mitochondrial function and whole-body metabolic flexibility.
Read more
Participant Population/Health Conditions: The study will involve 60 postmenopausal women aged 45-65 years living with overweight or obesity.
Main Questions: The main questions this study aims to answer are:
- What are the mitochondrial function and cellular characteristics of iBAT in postmenopausal women?
- Can aerobic exercise or five-day prolonged fasting improve mitochondrial function in iBAT and whole-body metabolic flexibility?
- Does combining aerobic exercise with prolonged fasting produce greater metabolic adaptations than either intervention alone?
- Are improvements in metabolic flexibility maintained four weeks after the intervention?
Participants Will:
Be randomized into one of four groups: control, aerobic exercise, prolonged fasting, or combined aerobic exercise plus prolonged fasting.
Follow their assigned intervention for five consecutive days. Undergo metabolic and physiological assessments before and after the intervention and again four weeks later.
Provide dorsocervical adipose tissue biopsies and biological samples to investigate mitochondrial function, adipocyte characteristics, and metabolic adaptations.
Comparison Group: Researchers will compare the effects of aerobic exercise, prolonged fasting, and their combination with a control condition to determine their effects on iBAT mitochondrial function and whole-body metabolic flexibility.
Read the detailed description
Postmenopause is associated with a substantial increase in cardiometabolic risk, partly driven by the decline in estrogen levels and alterations in cellular energy metabolism. Mitochondrial dysfunction has been documented in skeletal muscle of postmenopausal women and is associated with metabolic inflexibility, reduced fat oxidation, ectopic fat accumulation, and insulin resistance. However, whether mitochondrial dysfunction is also present in adipose tissue of postmenopausal women, and whether it can be reversed through lifestyle interventions, remains largely unknown.
Brown adipose tissue (BAT) is a mitochondria-rich and metabolically active tissue involved in thermogenesis and substrate utilization. Although human BAT has traditionally been studied in the supraclavicular region, emerging evidence from our research group suggests the presence of a metabolically active adipose tissue depot in the dorsocervical region, referred to as interscapular brown adipose tissue (iBAT). Preliminary observations indicate that this depot may have distinct metabolic characteristics. However, iBAT has not yet been characterized in postmenopausal women.
Aerobic exercise is a potent non-pharmacological stimulus for mitochondrial remodeling and improves mitochondrial biogenesis and oxidative capacity. Exercise-derived lactate may also promote adipose tissue browning and mitochondrial remodeling. Prolonged fasting induces profound metabolic adaptations characterized by increased fat mobilization and changes in substrate utilization. Preliminary data from our group suggest that five days of prolonged fasting substantially increase fat oxidation during exercise, providing a rationale for investigating whether fasting and exercise may have complementary effects on mitochondrial function and metabolic flexibility.
Based on this rationale, the main hypothesis of EMPOWER-BAT is that iBAT in postmenopausal women presents mitochondrial dysfunction and that aerobic exercise, five-day prolonged fasting, and their combination can improve mitochondrial function through lactate-related signaling pathways, leading to enhanced whole-body metabolic flexibility. The main objective is to characterize mitochondrial function in iBAT and determine the effects of these interventions on iBAT mitochondrial function and metabolic flexibility.
EMPOWER-BAT is a randomized controlled trial involving 60 postmenopausal women aged 45-65 years with a body mass index ≥25 kg/m². Participants will be randomized (1:1:1:1) into four groups: a control group maintaining its usual lifestyle; an aerobic exercise group performing supervised exercise for 60-90 minutes at 65% of heart rate reserve; a prolonged fasting group following a medically supervised fasting protocol providing approximately 600 kcal/day; or a combined group completing both exercise and fasting. All interventions will last five consecutive days.
Before and after the intervention, iBAT biopsies will be collected from the dorsocervical region to assess mitochondrial function and adipocyte characteristics. Metabolic and physiological assessments will include indirect calorimetry at rest and during exercise, body composition, cardiorespiratory fitness, and blood and urine biomarkers. Continuous glucose and ketone monitoring will also be performed during the intervention. Four weeks later, metabolic and physiological assessments will be repeated to determine whether changes in metabolic flexibility are maintained after participants return to their usual lifestyle.
- Conditions
- Cardiometabolic Diseases, Postmenopause
- Being tested
- Aerobic exercise, Prolonged fasting
- Keywords
- Brown adipose tissue, thermogenesis, women, postmenopause, exercise, fasting, metabolic flexibility
- Medical subject headings
- Motor Activity, Fasting
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Aerobic exerciseBehavioural
Participants will perform supervised aerobic exercise for 60-90 minutes per day at 65% of heart rate reserve on 5 consecutive days.
Prolonged fastingBehavioural
Participants will follow a medically supervised prolonged fasting protocol providing approximately 600 kcal/day for five consecutive days.
| Study group | Role | What they receive |
|---|---|---|
| Control | No intervention | n=15; maintaining their usual lifestyle without changes to diet or physical activity; Total 5 days |
| Aerobic exercise | Experimental | n=15; receiving supervised aerobic exercise for 60-90 minutes/day at 65% of heart rate reserve; Total 5 days Receives: Behavioral: Aerobic exercise |
| Prolonged fasting | Experimental | n=15; following a prolonged fasting protocol providing approximately 600 kcal/day; Total 5 days Receives: Behavioral: Prolonged fasting |
| Aerobic exercise + prolonged fasting | Experimental | n=15; receiving supervised aerobic exercise for 60-90 minutes/day at 65% of heart rate reserve and prolonged fasting providing approximately 600 kcal/day; Total 5 days Receives: Behavioral: Aerobic exercise; Behavioral: Prolonged fasting |
What is being measured
The primary outcome is the main question the study is designed to answer.
iBAT adipocyte composition and gene expression (snRNA-seq)
Change in adipocyte subpopulations and gene expression in dorsocervical iBAT assessed by single-nucleus RNA sequencing (snRNA-seq)
Measured: 1 week
Secondary outcomes (21)
iBAT mitochondrial respiration (Oroboros O2k).
Change in mitochondrial respiration in dorsocervical iBAT assessed by high-resolution respirometry.
Measured: 1 week
iBAT protein expression (Western blot)
Change in protein expression in dorsocervical iBAT assessed by Western blot, including markers related to thermogenesis and mitochondrial function.
Measured: 1 week
Total Body Fat Mass
Change in total body fat mass (kg) from baseline, assessed by dual-energy X-ray absorptiometry (DXA).
Measured: 5 weeks
Body Fat Percentage
Change in total body fat percentage (%) from baseline, assessed by dual-energy X-ray absorptiometry (DXA).
Measured: 5 weeks
Resting Metabolic Rate
Change in resting metabolic rate (kcal/day) from baseline, assessed by indirect calorimetry.
Measured: 5 weeks
Cardiorespiratory Fitness - Peak Oxygen Uptake (VO₂peak)
Change from baseline in peak oxygen uptake (VO₂peak; mL/kg/min), assessed during exercise testing with breath-by-breath gas exchange analysis.
Measured: 5 weeks
LDL Cholesterol
Change in fasting LDL cholesterol (mg/dL) from baseline, assessed in blood samples.
Measured: 5 weeks
Urinary Urea Nitrogen
Change from baseline in urinary urea nitrogen (UUN) concentration (mg/dL), assessed in urine samples as a marker of protein metabolism.
Measured: 5 weeks
Gut microbiota
Change in gut microbiota composition assessed in fecal samples.
Measured: 5 weeks
Fat-Free Mass
Change in total fat-free mass (kg) from baseline, assessed by dual-energy X-ray absorptiometry (DXA).
Measured: 5 weeks
Visceral Adipose Tissue (VAT) Fat Mass
Change in visceral adipose tissue (VAT) fat mass (g) from baseline, assessed by dual-energy X-ray absorptiometry (DXA).
Measured: 5 weeks
Subcutaneous Adipose Tissue (SAT) Fat Mass
Change in subcutaneous adipose tissue (SAT) fat mass (g) from baseline, assessed by dual-energy X-ray absorptiometry (DXA).
Measured: 5 weeks
Fat Oxidation Rate at Rest
Change in resting fat oxidation rate (g/min) from baseline, calculated from oxygen consumption (VO₂) and carbon dioxide production (VCO₂) measured by indirect calorimetry.
Measured: 5 weeks
Carbohydrate Oxidation Rate at Rest
Change in resting carbohydrate oxidation rate (g/min) from baseline, calculated from oxygen consumption (VO₂) and carbon dioxide production (VCO₂) measured by indirect calorimetry.
Measured: 5 weeks
HDL Cholesterol
Change in fasting HDL cholesterol (mg/dL) from baseline, assessed in blood samples.
Measured: 5 weeks
Fasting Glucose
Change in fasting blood glucose (mg/dL) from baseline.
Measured: 5 weeks
Fasting Insulin
Change in fasting insulin concentration (µIU/mL) from baseline, assessed in blood samples.
Measured: 5 weeks
Triglycerides
Change in fasting triglyceride concentration (mg/dL) from baseline, assessed in blood samples.
Measured: 5 weeks
C-Reactive Protein (CRP)
Change in C-reactive protein concentration (mg/L) from baseline, assessed in blood samples.
Measured: 5 weeks
Fat Oxidation During Exercise
Change from baseline in fat oxidation rate (g/min) during exercise, estimated by indirect calorimetry using a COSMED Quark metabolic cart.
Measured: 5 weeks
Carbohydrate Oxidation During Exercise
Change from baseline in carbohydrate oxidation rate (g/min) during exercise, estimated by indirect calorimetry using a COSMED Quark metabolic cart.
Measured: 5 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Sep 2026
- Study start1 Sep 2027 (estimated)
- Primary completionSep 2029 (estimated)
- Study completionSep 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cardiometabolic DiseasesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- This study will consist of a randomized controlled trial in which 60 postmenopausal women with a BMI ≥27 kg/m² will be randomly assigned (1:1:1:1) to a control group (n=15; maintaining their usual lifestyle), an aerobic exercise group (n=15; supervised exercise for 60-90 minutes/day at 65% heart rate reserve), a prolonged fasting group (n=15; approximately 600 kcal/day), or a combined exercise plus fasting group (n=15; completing both interventions). All interventions will last five consecutive days.
- Masking
- Single blind
- Who is masked
- Investigator
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Universidad de Almeria
- Sponsor type
- University, hospital or other
- Collaborators
- Leiden University Medical Center, ETH Zurich (Switzerland), Buchinger Wilhelmi Development & Holding GmbH
- Responsible party
- Principal investigator, Borja Martínez Tellez, Universidad de Almeria
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07837752
- Sponsor's protocol ID
- PID2025-173649OB-I00
- Acronym
- EMPOWER-BAT
- Status last verified
- Sep 2026
- First submitted
- 9 Sep 2026
- Last updated
- 23 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 23 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Exercise and Prolonged Fasting to Improve Interscapular Brown Fat Mitochondrial Function and Enhance Metabolic Flexibility in Postmenopausal Women (EMPOWER-BAT)
- ClinicalTrials.gov ID
- NCT07837752
- Acronym / sponsor ID
- EMPOWER-BAT / PID2025-173649OB-I00
- Conditions
- Cardiometabolic Diseases, Postmenopause
- Keywords
- Brown adipose tissue, thermogenesis, women, postmenopause, exercise, fasting, metabolic flexibility
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- Universidad de AlmeriaUniversity, hospital or other
- Collaborators
- Leiden University Medical Center, ETH Zurich (Switzerland), Buchinger Wilhelmi Development & Holding GmbH
- Study start
- 1 Sep 2027 (estimated)
- Primary completion
- Sep 2029 (estimated)
- Study completion
- Sep 2029 (estimated)
- First posted
- 23 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Type of Study: Clinical Trial
Goal: The goal of this clinical trial is to investigate mitochondrial function in interscapular brown adipose tissue (iBAT) in postmenopausal women and determine whether aerobic exercise, prolonged fasting, or their combination can improve iBAT mitochondrial function and whole-body metabolic flexibility.
Participant Population/Health Conditions: The study will involve 60 postmenopausal women aged 45-65 years living with overweight or obesity.
Main Questions: The main questions this study aims to answer are:
- What are the mitochondrial function and cellular characteristics of iBAT in postmenopausal women?
- Can aerobic exercise or five-day prolonged fasting improve mitochondrial function in iBAT and whole-body metabolic flexibility?
- Does combining aerobic exercise with prolonged fasting produce greater metabolic adaptations than either intervention alone?
- Are improvements in metabolic flexibility maintained four weeks after the intervention?
Participants Will:
Be randomized into one of four groups: control, aerobic exercise, prolonged fasting, or combined aerobic exercise plus prolonged fasting.
Follow their assigned intervention for five consecutive days. Undergo metabolic and physiological assessments before and after the intervention and again four weeks later.
Provide dorsocervical adipose tissue biopsies and biological samples to investigate mitochondrial function, adipocyte characteristics, and metabolic adaptations.
Comparison Group: Researchers will compare the effects of aerobic exercise, prolonged fasting, and their combination with a control condition to determine their effects on iBAT mitochondrial function and whole-body metabolic flexibility.
Detailed description
Postmenopause is associated with a substantial increase in cardiometabolic risk, partly driven by the decline in estrogen levels and alterations in cellular energy metabolism. Mitochondrial dysfunction has been documented in skeletal muscle of postmenopausal women and is associated with metabolic inflexibility, reduced fat oxidation, ectopic fat accumulation, and insulin resistance. However, whether mitochondrial dysfunction is also present in adipose tissue of postmenopausal women, and whether it can be reversed through lifestyle interventions, remains largely unknown.
Brown adipose tissue (BAT) is a mitochondria-rich and metabolically active tissue involved in thermogenesis and substrate utilization. Although human BAT has traditionally been studied in the supraclavicular region, emerging evidence from our research group suggests the presence of a metabolically active adipose tissue depot in the dorsocervical region, referred to as interscapular brown adipose tissue (iBAT). Preliminary observations indicate that this depot may have distinct metabolic characteristics. However, iBAT has not yet been characterized in postmenopausal women.
Aerobic exercise is a potent non-pharmacological stimulus for mitochondrial remodeling and improves mitochondrial biogenesis and oxidative capacity. Exercise-derived lactate may also promote adipose tissue browning and mitochondrial remodeling. Prolonged fasting induces profound metabolic adaptations characterized by increased fat mobilization and changes in substrate utilization. Preliminary data from our group suggest that five days of prolonged fasting substantially increase fat oxidation during exercise, providing a rationale for investigating whether fasting and exercise may have complementary effects on mitochondrial function and metabolic flexibility.
Based on this rationale, the main hypothesis of EMPOWER-BAT is that iBAT in postmenopausal women presents mitochondrial dysfunction and that aerobic exercise, five-day prolonged fasting, and their combination can improve mitochondrial function through lactate-related signaling pathways, leading to enhanced whole-body metabolic flexibility. The main objective is to characterize mitochondrial function in iBAT and determine the effects of these interventions on iBAT mitochondrial function and metabolic flexibility.
EMPOWER-BAT is a randomized controlled trial involving 60 postmenopausal women aged 45-65 years with a body mass index ≥25 kg/m². Participants will be randomized (1:1:1:1) into four groups: a control group maintaining its usual lifestyle; an aerobic exercise group performing supervised exercise for 60-90 minutes at 65% of heart rate reserve; a prolonged fasting group following a medically supervised fasting protocol providing approximately 600 kcal/day; or a combined group completing both exercise and fasting. All interventions will last five consecutive days.
Before and after the intervention, iBAT biopsies will be collected from the dorsocervical region to assess mitochondrial function and adipocyte characteristics. Metabolic and physiological assessments will include indirect calorimetry at rest and during exercise, body composition, cardiorespiratory fitness, and blood and urine biomarkers. Continuous glucose and ketone monitoring will also be performed during the intervention. Four weeks later, metabolic and physiological assessments will be repeated to determine whether changes in metabolic flexibility are maintained after participants return to their usual lifestyle.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (investigator)
- Number of arms
- 4
- Model description
- This study will consist of a randomized controlled trial in which 60 postmenopausal women with a BMI ≥27 kg/m² will be randomly assigned (1:1:1:1) to a control group (n=15; maintaining their usual lifestyle), an aerobic exercise group (n=15; supervised exercise for 60-90 minutes/day at 65% heart rate reserve), a prolonged fasting group (n=15; approximately 600 kcal/day), or a combined exercise plus fasting group (n=15; completing both interventions). All interventions will last five consecutive days.
| Arm | Type | Receives |
|---|---|---|
| Control | No intervention | –n=15; maintaining their usual lifestyle without changes to diet or physical activity; Total 5 days |
| Aerobic exercise | Experimental | Behavioral: Aerobic exercisen=15; receiving supervised aerobic exercise for 60-90 minutes/day at 65% of heart rate reserve; Total 5 days |
| Prolonged fasting | Experimental | Behavioral: Prolonged fastingn=15; following a prolonged fasting protocol providing approximately 600 kcal/day; Total 5 days |
| Aerobic exercise + prolonged fasting | Experimental | Behavioral: Aerobic exercise, Behavioral: Prolonged fastingn=15; receiving supervised aerobic exercise for 60-90 minutes/day at 65% of heart rate reserve and prolonged fasting providing approximately 600 kcal/day; Total 5 days |
Who may qualify
- Ages
- 45 to 65 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Women aged 45 to 65 years.
- Postmenopausal status, defined as ≥ 12 consecutive months without menstruation.
- Women with amenorrhea shorter than 12 months will be included if their follicle-stimulating hormone levels are >30IU/liter.
- BMI between ≥25 kg/m2.
- Sedentary or low-active (not meeting physical activity guidelines).
Key exclusion criteria (9 listed)
- Diabetes mellitus (determined based on fasting glucose levels defined by ADA criteria).
- Any other active endocrine disease (thyroid disease, any signs of Cushing's syndrome, adrenal disease and lipid-associated disorders such as familial hypercholesterolemia).
- Any cardiac disease (i.e., ischemic cardiac disease, arrhythmias, severe heart failure).
- Use of medication known to influence glucose and/or lipid metabolism or brown fat activity (e.g., beta-blockers, antidepressants, corticosteroids).
- Current or recent (past 6 months) use of hormone replacement therapy, including systemic estrogen therapy (oral or transdermal), combined estrogen-progestin therapy, tibolone, or selective estrogen receptor modulators.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Aerobic exerciseParticipants will perform supervised aerobic exercise for 60-90 minutes per day at 65% of heart rate reserve on 5 consecutive days. | Behavioural | Aerobic exercise, Aerobic exercise + prolonged fasting |
| Prolonged fastingParticipants will follow a medically supervised prolonged fasting protocol providing approximately 600 kcal/day for five consecutive days. | Behavioural | Aerobic exercise + prolonged fasting, Prolonged fasting |
Primary outcome
iBAT adipocyte composition and gene expression (snRNA-seq)
Time frame: 1 week
Change in adipocyte subpopulations and gene expression in dorsocervical iBAT assessed by single-nucleus RNA sequencing (snRNA-seq)
21 secondary outcomes
iBAT mitochondrial respiration (Oroboros O2k).
Time frame: 1 week
iBAT protein expression (Western blot)
Time frame: 1 week
Total Body Fat Mass
Time frame: 5 weeks
Body Fat Percentage
Time frame: 5 weeks
Resting Metabolic Rate
Time frame: 5 weeks
Cardiorespiratory Fitness - Peak Oxygen Uptake (VO₂peak)
Time frame: 5 weeks
LDL Cholesterol
Time frame: 5 weeks
Urinary Urea Nitrogen
Time frame: 5 weeks
Gut microbiota
Time frame: 5 weeks
Fat-Free Mass
Time frame: 5 weeks
Visceral Adipose Tissue (VAT) Fat Mass
Time frame: 5 weeks
Subcutaneous Adipose Tissue (SAT) Fat Mass
Time frame: 5 weeks
Fat Oxidation Rate at Rest
Time frame: 5 weeks
Carbohydrate Oxidation Rate at Rest
Time frame: 5 weeks
HDL Cholesterol
Time frame: 5 weeks
Fasting Glucose
Time frame: 5 weeks
Fasting Insulin
Time frame: 5 weeks
Triglycerides
Time frame: 5 weeks
C-Reactive Protein (CRP)
Time frame: 5 weeks
Fat Oxidation During Exercise
Time frame: 5 weeks
Carbohydrate Oxidation During Exercise
Time frame: 5 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Sep 2026.
- Individual participant dataSharing planned: Yes
Related trials for Cardiometabolic Diseases
Enrolling by invitation
MTM2MTG Pilot Ancillary Study
Diet, Healthy, HbA1c
Not yet recruitingObservational study
Qatar Cardiometabolic Cohort
Cardiometabolic Diseases
Not yet recruitingObservational study
A Natural History of Cardiometabolic Disease Among US Bhutanese: Developing the Cross-Sectional Bhutanese Community of Central Ohio Health Study to Understand Acculturation as Synergizing Socioenvironmental and Biobehavioral Risk Factors Propagating ...
Cardiometabolic Risk Factors, Mental Health
Not yet recruiting
Effects of Increased Water Intake on Hormonal Response, Hydration Status, and Physical Function in Low-drinking Older Adults
Dehydrated, Water-Electrolyte Imbalance, Malnutrition, Dehydration (Physiology)
Active, not recruiting
Nested Pilot Study Comparing Two Treatments to Reduce Type 2 Diabetes Risk in At-Risk Delawareans
Prediabetes
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Aerobic exercise and Prolonged fasting in people with Cardiometabolic Diseases and Postmenopause, run by Universidad de Almeria at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 23 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Borja Martínez Téllez, PhD (+34 950215334, borjammt@ual.es), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
iBAT adipocyte composition and gene expression (snRNA-seq) (time frame: 1 week). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Sep 2026.